Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2013, Vol. 33 Issue (8): 127-133    DOI:
    
The Origin and Implementation of Cell Transplantation Therapy
WANG Dian-liang
Department of Pharmacy, The Second Artillery General Hospital, Beijing 100088, China
Download: HTML   PDF(674KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  Cell transplantation therapy that includes general somatic cell transplantation, immune cell transplantation and stem cell transplantation has passed through a lengthy development history. The principle of cell transplantation therapy is by so far not completely clear. Cell transplantation therapy mainly contains organ specificity, cell homing, trans-differentiation, immune mediation and self-renewing, etc. The ways of cell transplantation therapy include minimally invasive transplant, local injection transplant, intra-arterial injection transplant, intra-venous injection transplant, and cavum subarachnoidale transplant, etc.

Key wordsCell transplantation      Cell theraphy      Somatic cell      Immune cell      Stem cell     
Received: 08 July 2013      Published: 25 August 2013
ZTFLH:  Q819  
Cite this article:

WANG Dian-liang. The Origin and Implementation of Cell Transplantation Therapy. China Biotechnology, 2013, 33(8): 127-133.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2013/V33/I8/127

[1] Aduen J F, Castello R, Lazano M M, et al. An alternative echocardiographic method to estimate mean pulmonary artery pressure: diagnostic and clinical implications. J Am Soc Echocardiogr 2009,22:814-819.
[2] Bouhadir K H, Lee K Y, Alsberg E, et al. Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol Prog, 2001,17:945-950.
[3] Boyle A J, Schulman S P, Hare J M, et al. Is stem cell therapy ready for patients? Stem cell therapy for cardiac repair. Circulation, 2006,114:339-352.
[4] Breyer A, Estharabadi N, Oki M, et al. Multipotent adult progenitor cell isolation and culture procedures. Exp Hematol, 2006,34:1596-1601.
[5] Carpentino J E, Hynes M J, Appelman H D, et al. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res, 2009,69(20):8208-8215.
[6] Chen F M, Zhang M, Wu Z F. Toward delivery of multiple growth factors in tissue engineering. Biomaterials, 2010,31:6279-6308.
[7] Chen Y, Teng F Y, Tang B L. Coaxing bone marrow stromal mesenchymal stem cells towards neuronal differentiation: progress and uncertainties. Cell Mol Life Sci, 2006,63:1649-1657.
[8] Ferdinandy P, Schulz R, Baxter G F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and post conditioning. Pharmacol Rev, 2007,59:418-458.
[9] Hayashi S, Peranteau W H, Shaaban A F, et al. Complete allogeneic hema-topoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion. Blood, 2002,100:804-812.
[10] Hermann A, Liebau S, Gastl R, et al. Comparative analysis of neuroectodermal differentiation capacity of human bonemarrowstromal cells using various conversion protocols. J Neurosci Res, 2006,83:1502-1514.
[11] Ieda M, Fu J D, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell ,2010,142:375-386.
[12] Jas X, D'Armini A M, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, placebo-controlled trial. J Am Coll Cardiol, 2008,52(25):2127-2134.
[13] Kawasaki B T, Hurt E M, Mistree T, et al. Targeting cancer stem cells with phytochemicals. Mol Interv, 2008,8(4):174-184.
[14] Zierold C, Carlson M A, Obodo U C, et al. Developing mechanistic insights into cardiovascular cell therapy: cardiovascular cell therapy research network biorepository core laboratory rationale. American Heart Journal, 2011, 162(6):973-980.
[15] Zhu, D L, Chen Li, Hong T. Position statement of the Chinese diabetes society regarding stem cell therapy for diabetes. Journal of Diabetes, 2012, 4(1):18-21.
[16] Assmus B, Fischer-Rasokat U, Honold J, et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: Results of the TOPCARE-CHD registry. Circ Res, 2007,100:1234.
[17] Heldman A W, Hare J M. Cell therapy for myocardial infarction:special delivery. J Mol Cell Cardiol, 2007,44:473-476.
[18] Johnson P C, Mikos A G, Fisher J P, et al. Strategic directions in tissue engineering. Tissue Eng, 2007,13:2827-2837.
[19] von Bahr L, Sundberg B, Lunnies L, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biology of Blood and Marrow Transplantation, 2012, 18 (4):557-564.
[20] Titomanlio L, Kavelaars A, Dalous J, et al. Stem cell therapy for neonatal brain injury: perspectives and challenges. Ann Neurol, 2011, 70(5):698-712.
[1] QIAN Yu,DING Xiao-yu,LIU Zhi-qiang,YUAN Zeng-qiang. An Efficient Monoclonal Establishment Method of Genetically Modified Human Pluripotent Stem Cells[J]. China Biotechnology, 2021, 41(8): 33-41.
[2] LI Kai-xiu,SI Wei. Progress in the Treatment of Inflammatory Bowel Diseases by Exosomes Derived from Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(7): 66-73.
[3] WANG Yu-xuan,CHEN Ting,ZHANG Yong-liang. Research Progress on the Biological Function of MiR-148[J]. China Biotechnology, 2021, 41(7): 74-80.
[4] ZHAO Jiu-mei,WANG Zhe,LI Xue-ying. Role of Signal Pathways and Related Factors Regulating Cartilage Formation in Bone Differentiation of Bone Marrow Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(10): 62-72.
[5] CHEN Fei,WANG Xiao-bing,XU Zeng-hui,QIAN Qi-jun. Molecular Mechanism and Clinical Research Progress of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus[J]. China Biotechnology, 2020, 40(7): 59-69.
[6] DAI Qi-nan,ZHANG Jing-hong. Advances in Molecular Mechanisms Related to Tumor Multi-drug Resistance, Autophagy, DNA Repair and Tumor Stem Cells[J]. China Biotechnology, 2020, 40(4): 69-77.
[7] YUAN Ya-kun,LIU Guang-yang,LIU Yong-jun,XIE Ya-fang,WU Hao. Comparison of Research and Clinical Transformation on Mesenchymal Stem Cells between China and the US[J]. China Biotechnology, 2020, 40(4): 97-107.
[8] YANG Dan,TIAN Hai-shan,LI Xiao-kun. Research Progress of Fibroblast Growth Factor 5[J]. China Biotechnology, 2020, 40(3): 117-124.
[9] CHEN Li-jun,QU Jing-jing,XIANG Charlie. Therapeutic Potentials, Clinical Studies, and Application Prospects of Mesenchymal Stem Cells in 2019 Novel Coronavirus (COVID-19)[J]. China Biotechnology, 2020, 40(11): 43-55.
[10] QIU Dan-dan,LU Cai-xia,DAI Jie-jie. Application of Hepatocyte-like Cells Derived from Induced Pluripotent Stem Cells in HCV Infection Model[J]. China Biotechnology, 2020, 40(11): 67-72.
[11] ZHU Yongzhao,TAO Jin,REN Meng-meng,XIONG Ran,HE Ya-qin,ZHOU Yu,LU Zhen-hui,DU Yong,YANG Zhi-hong. Autophagy Protects Against Apoptosis of Human Placental Mesenchymal Stem Cells of Fetal Origin Induced by Tumor Necrosis Fator-α[J]. China Biotechnology, 2019, 39(9): 62-67.
[12] Yu-sheng OU,Hong-jun ZHENG,Shi ZHONG,Yi LI. TAEST16001:TCR Affinity Enhanced Specific-T-cell Therapy[J]. China Biotechnology, 2019, 39(2): 49-61.
[13] Yue-lei FAN,Jiao LU,Da-ming CHEN,Kai-yun MAO. Strategies for Stem Cell Patent Evaluation and Patent Transfer and Transformation[J]. China Biotechnology, 2019, 39(1): 99-106.
[14] Wen-wen SHI,Lei ZHANG. Current Research of Micro Mechanical Environmental Effects on Mesenchymal Stem Cells’ Differentiation[J]. China Biotechnology, 2018, 38(8): 76-83.
[15] Yan ZHENG,Huan YAO,Ke YANG. SFRP5 Inhibites Osteogenic Differentiation of Human Umbilical Cord-derived Mesenchymal Stem Cells Induced by BMP9[J]. China Biotechnology, 2018, 38(7): 7-13.